NCT01405677View on ClinicalTrials.gov

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Hepatitis A
Interventions
BIOLOGICAL

Epaxal 0.25 mL

12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)

BIOLOGICAL

Epaxal 0.5 mL

24 IU hepatitis A antigen coupled to IRIV

BIOLOGICAL

Havrix Junior 0.5 mL

720 EU hepatitis A antigen absorbed onto aluminum hydroxide

Trial Locations (2)

B-2018

Sint-Vincentiusziekenhuis, Antwerp

BE-2610

Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01405677 - Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine | Biotech Hunter | Biotech Hunter